Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/18/2012CA2832467A1 1,3 oxazines as bace1 and/or bace2 inhibitors
10/18/2012CA2832073A1 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
10/18/2012CA2831388A1 Asymmetrically substituted anthrapyridazone derivatives as cytostatics
10/18/2012CA2827739A1 Prostate cancer therapy with hsp90 inhibitory compounds
10/17/2012EP2511371A1 Anticancer anti-mortalin peptide antibodies
10/17/2012EP2511301A2 Human antibodies to ERBB2
10/17/2012EP2511276A1 Pyrrolo[2,3-d]pyrimidine derivative
10/17/2012EP2511275A1 Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
10/17/2012EP2511264A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
10/17/2012EP2510926A1 Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
10/17/2012EP2510924A1 Solid dispersions containing 20-o- -d-glucopyranosyl-20(s)-protopanaxadiol
10/17/2012EP2510358A1 Methods of inhibiting metastatic cancer by administration of streptolysin o
10/17/2012EP2510088A2 Oncolytic rhabdovirus
10/17/2012EP2510012A1 Anti-c4.4a antibodies and uses thereof
10/17/2012EP2510010A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use
10/17/2012EP2510007A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510006A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510005A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510004A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510003A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510002A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2509979A1 Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
10/17/2012EP2509974A1 Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
10/17/2012EP2509964A1 Heterocyclic sulfonamide derivatives
10/17/2012EP2509963A1 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
10/17/2012EP2509955A1 Pyrazole derivatives as modulators of calcium release -activated calcium channel
10/17/2012EP2509943A1 2-methylene-19,26-nor-(20s)-l&-hydroxyvitamin d3
10/17/2012EP2509634A2 Stable formulations for lyophilizing therapeutic particles
10/17/2012EP2509633A2 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
10/17/2012EP2509630A1 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
10/17/2012EP2509628A2 Sr-bi as a predictor of human female infertility and responsiveness to treatment
10/17/2012EP2509626A1 Anti-vegf-c antibodies and methods using same
10/17/2012EP2509623A1 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant
10/17/2012EP2509620A2 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
10/17/2012EP2509618A2 Systemic administration of an agent that permeabilises tumour vasculature
10/17/2012EP2509601A1 Small pyrimidine derivatives and methods of use thereof
10/17/2012EP2509600A1 Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
10/17/2012EP2509599A2 Method of treating pancreatic cancer
10/17/2012EP2509597A1 Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
10/17/2012EP2509593A2 Therapeutic use of protein-polymer conjugates
10/17/2012EP2509592A1 Bibw 2992 for use in the treatment of triple negative breast cancer
10/17/2012CN1948274B Verakanol derivative, preparation method and use thereof
10/17/2012CN1927183B Antineoplasma medicine pidorubicin slow release microsphere preparation and method for preparing same
10/17/2012CN1922171B Pyrimidine derivative
10/17/2012CN102741294A Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID 2)
10/17/2012CN102741292A A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
10/17/2012CN102741291A Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012CN102741289A Antibodies specific for claudin 6 (cldn6)
10/17/2012CN102741271A IMP-3 oligopeptides and vaccines including the same
10/17/2012CN102741264A Prostate specific membrane antigen inhibitors
10/17/2012CN102741262A Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment
10/17/2012CN102741261A New aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the met family
10/17/2012CN102741260A New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
10/17/2012CN102741257A Spiroindolinone pyrrolidines
10/17/2012CN102741253A Pi3k (delta) selective inhibitors
10/17/2012CN102741243A Novel compound amycolatopsis derivative, and production process and use of same
10/17/2012CN102740892A Nanoparticle carrier systems based on poly(DL-lactic-co-glycolic acid) (PLGA) for photodynamic therapy (PDT)
10/17/2012CN102740888A Antibodies to IL-6 and use there
10/17/2012CN102740887A Combination immunotherapy for the treatment of cancer
10/17/2012CN102740885A Treatment of cancer involving mutated kras or braf genes
10/17/2012CN102740875A Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
10/17/2012CN102740874A Methods and compositions for liquidation of tumors
10/17/2012CN102740860A Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases
10/17/2012CN102740841A Solid dispersions containing 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol
10/17/2012CN102740834A Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
10/17/2012CN102740833A Parenteral formulations of gemcitabine derivatives
10/17/2012CN102735843A JMJD8 gene and expression product for inhibiting growth of hepatoma cells
10/17/2012CN102732608A Marker for diagnosing liver cancer and application thereof
10/17/2012CN102732561A Recombinant adenovirus carrier with deletion of IVa2 gene function and preparation method thereof
10/17/2012CN102732550A Expression of human s1CD80 protein in Pichia pastoris system
10/17/2012CN102732543A Tumor genetically-engineered vaccine utilizing mucin-1 and survivin as target sites
10/17/2012CN102732524A Use of histidine-rich glycoprotein (HRG)-like lampetra japonica Lj-RGD3 all RGD deletion mutant Lj-112 in antitumor drug
10/17/2012CN102732515A Nucleotide sequence and application thereof
10/17/2012CN102732498A Application of protease tablysin to preparation of medicament for treating tumor
10/17/2012CN102731772A Camptothecin compound pegylated derivatives
10/17/2012CN102731736A PtBA-b-PEG-b-PtBA block copolymer, and preparation method and application thereof
10/17/2012CN102731666A Method for extracting polysaccharide from cordyceps militaris medium
10/17/2012CN102731658A Tat PTD-Endostatin recombination protein, preparation method and application thereof
10/17/2012CN102731611A Leptomycin derivatives
10/17/2012CN102731610A 26-thio or -seleno spirostanol saponin, synthesis method and application thereof
10/17/2012CN102731597A Abelmoschus manihot extract and novel application of chemical components thereof
10/17/2012CN102731591A Anti-tumor anti-virus compound, preparation method and application thereof
10/17/2012CN102731590A Coumarin glucoside, preparation method and application of coumarin glucoside
10/17/2012CN102731586A Preparation technology of stilbene glucoside in polygonum multiflorum
10/17/2012CN102731580A Binuclear platinum (II)-diphosphonic acid coordination compound, preparation method and application thereof
10/17/2012CN102731577A Synthetic method for ruthenium metal complex
10/17/2012CN102731573A Hydroxyl phosphate amino acid ester derivatives of Brefeldin A, preparation method thereof, and application thereof
10/17/2012CN102731565A Water-soluble derivative of diphenylethene compounds, preparation method and usage thereof
10/17/2012CN102731562A Triphenyltin coordination compound, preparation method thereof and application
10/17/2012CN102731561A Dibutyltin coordination compound, preparation method of dibutyltin coordination compound and application of ibutyltin coordination compound
10/17/2012CN102731526A New ansamitocin compounds and preparation method thereof
10/17/2012CN102731525A Benzomorpholine derivative
10/17/2012CN102731519A P-nitro aryl methoxycamptothecine anoxic activated prodrug used for antitumor drug
10/17/2012CN102731518A O-nitro aryl methoxycamptothecine anoxic activated prodrug used for antitumor drug
10/17/2012CN102731517A Camptothecin derivative, and preparation method and application thereof to preparation of medicament for treating tumor
10/17/2012CN102731516A Novel camptothecin derivatives having antineoplastic activity
10/17/2012CN102731493A Anti-tumor compound containing benzothiazole heterocyclic structure and application thereof
10/17/2012CN102731488A Benzimidazole derivatives, preparation method thereof, pharmaceutical composition thereof and application thereof
10/17/2012CN102731485A 4-(substituted phenylamino)quinazoline derivative, its preparation method, pharmaceutical composition and application
10/17/2012CN102731464A Sesquiterpene lactone compound, its preparation methods and application
1 ... 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 ... 2211